紫杉醇联合氟尿嘧啶对比顺铂联合氟尿嘧啶在局部晚期食管鳞癌根治性同步放化疗中的随机多中心III期临床试验
该随机多中心III期试验纳入436例局部晚期食管鳞癌患者,比较紫杉醇联合氟尿嘧啶方案与顺铂联合氟尿嘧啶方案在根治性同步放化疗中的疗效与安全性。主要终点3年总生存率在两组间无显著差异(55.4% vs 51.8%,HR 0.905,P=0.448)。紫杉醇联合氟尿嘧啶组急性3级及以上贫血、血小板减少、厌食、恶心、呕吐和乏力发生率显著更低,但白细胞减少、放射性皮炎和放射性肺炎发生率更高。
要点
- 紫杉醇联合氟尿嘧啶方案对比顺铂联合氟尿嘧啶方案未显著延长局部晚期食管鳞癌患者的3年总生存(55.4% vs 51.8%,HR 0.905,P=0.448)。
- 两组3年无进展生存率亦无显著差异(43.7% vs 45.5%,HR 0.973,P=0.828)。
- 紫杉醇联合氟尿嘧啶组急性3级及以上贫血、血小板减少、厌食、恶心、呕吐和乏力发生率显著更低,但白细胞减少、放射性皮炎和放射性肺炎发生率更高(P<0.05)。
核心结论
- 在局部晚期食管鳞癌根治性同步放化疗中,紫杉醇联合氟尿嘧啶方案对比标准顺铂联合氟尿嘧啶方案未显著延长总生存。
研究设计与样本
- 随机、多中心、III期临床试验,2012年4月至2015年7月从6个中心按1:1比例招募436例局部晚期食管鳞癌患者。
- 放疗剂量为61.2 Gy分34次照射。
- 主要终点为3年总生存率。
主要发现
- 存活患者中位随访时间为48.7个月(四分位距42.6-60.9)。
- 紫杉醇联合氟尿嘧啶组3年总生存率为55.4%,顺铂联合氟尿嘧啶组为51.8%(风险比0.905 [95% CI 0.698-1.172];P=0.448)。
- 紫杉醇联合氟尿嘧啶组3年无进展生存率为43.7%,顺铂联合氟尿嘧啶组为45.5%(风险比0.973 [95% CI 0.762-1.243];P=0.828)。
- 对比顺铂联合氟尿嘧啶组,紫杉醇联合氟尿嘧啶组急性3级及以上贫血、血小板减少、厌食、恶心、呕吐和乏力发生率显著更低(P<0.05)。
- 对比顺铂联合氟尿嘧啶组,紫杉醇联合氟尿嘧啶组急性3级及以上白细胞减少、放射性皮炎和放射性肺炎发生率显著更高(P<0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This trial aimed to assess the efficacy and safety of the paclitaxel plus fluorouracil regimen versus the cisplatin plus fluorouracil regimen in definitive concurrent chemoradiotherapy (dCRT) in patients with locally advanced esophageal squamous cell carcinoma (ESCC). PATIENTS AND METHODS: Patients with locally advanced ESCC were enrolled and randomly assigned to either the paclitaxel plus fluorouracil group or the cisplatin plus fluorouracil group. The patients in the paclitaxel plus fluorouracil group were treated with paclitaxel and fluorouracil one cycle per week in dCRT for five cycles followed by paclitaxel and fluorouracil one cycle per month in consolidation chemotherapy for two cycles. The patients in the cisplatin/5-fluorouracil group were treated with cisplatin and fluorouracil one cycle per month in dCRT for two cycles followed by two cycles in consolidation chemotherapy. The radiotherapy dose was 61.2 Gy delivered in 34 fractions. The primary end point was 3-year overall survival (OS). RESULTS: Four hundred thirty-six patients with ESCC in six centers were recruited at a 1:1 ratio between April 2012 and July 2015. The median follow-up of the surviving patients was 48.7 months (interquartile range, 42.6-60.9). The 3-year OS was 55.4% in the paclitaxel plus fluorouracil group and 51.8% in the cisplatin plus fluorouracil group (hazard ratio, 0.905 [95% CI, 0.698 to 1.172]; P = .448). The 3-year progression-free survival was also not significantly different between the paclitaxel plus fluorouracil group and the cisplatin plus fluorouracil group (43.7% v 45.5%, respectively; hazard ratio, 0.973 [95% CI, 0.762 to 1.243]; P = .828). Compared with the cisplatin plus fluorouracil group, the paclitaxel plus fluorouracil group had significantly lower incidences of acute grade 3 or higher anemia, thrombocytopenia, anorexia, nausea, vomiting, and fatigue (P < .05), but higher incidences of acute grade 3 or higher leukopenia, radiation dermatitis, and radiation pneumonitis (P < .05). CONCLUSION: The paclitaxel plus fluorouracil regimen did not significantly prolong the OS compared with the standard cisplatin plus fluorouracil regimen in dCRT in patients with locally advanced ESCC.
引用
- Chen Y, Ye J, Zhu Z, et al. Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial. J Clin Oncol. 2019. PMID: 30920880. doi:10.1200/JCO.18.02122
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。